Africa’s $8 Billion Diagnostic Opportunity — And Why It’s Being Missed. A Decision-Leadership opinion by Anjo De Heus

 

For decades, the conversation around healthcare in Africa has focused on treatment.

New drugs. New therapies. Emergency response.

But the real leverage point has been hiding in plain sight.

Diagnostics.

Every year, millions of people across Africa die not because diseases are untreatable — but because they are detected too late. Cancer diagnosed at stage four. Diabetes discovered after complications set in. Tuberculosis identified only after transmission has already occurred.

This is not a technology problem.
It is a system design failure.

The Scale of the Opportunity Few Are Talking About

Africa is home to 1.5 billion people.

In high-income countries, the average person undergoes 4–7 diagnostic tests per year. In low- and middle-income settings, that number drops below one.

Even with conservative assumptions — one diagnostic test per person per year — Africa represents 1.5 billion tests annually.

Not all diagnostics require complex laboratories or invasive blood draws. In fact, 30–40% of essential diagnostics can be delivered through saliva-based testing, especially for:

• Infectious diseases (TB, HIV, malaria, respiratory)
• Chronic diseases (diabetes, cardiovascular risk)
• Cancer screening markers
• Surveillance and outbreak detection

That alone represents 450–900 million tests per year.

At a conservative system value of $3–6 per test, this creates a $1.3–5.4 billion annual diagnostics market — before telehealth, data systems, or manufacturing are included.

When integrated properly, the full ecosystem exceeds $8 billion per year.

Yet most of this value never touches African economies.

Why the Current Model Is Broken

Today’s diagnostic ecosystem in Africa is defined by:

• Heavy reliance on imports
• Fragmented pilots that never scale
• Technologies designed for hospitals, not communities
• Donor programs that end before systems mature

As a result:

• Countries remain dependent
• Jobs are lost
• Data is fragmented
• Preparedness is weakened

Diagnostics are treated as consumables, not infrastructure.

That is the core mistake.

Why Global Leaders Are Betting on This Shift

There is a reason companies are investing heavily in decentralized diagnostics and non-invasive testing.

They see what the global health system is slowly realizing:

Early detection is the most scalable form of prevention.

Saliva-based diagnostics are not a niche innovation. They are a platform shift — enabling testing:

• Without needles
• Without cold chains
• Without centralized labs
• Without highly specialized staff

When paired with telehealth and digital care pathways, diagnostics stop being an endpoint and become the entry point to care.

From Aid to Architecture: A Different Model

The real opportunity is not to run another pilot.

It is to build national diagnostic ecosystems that combine:

1. Decentralized saliva diagnostics
2. Telehealth and referral pathways
3. Local assembly and manufacturing
4. Government alignment and data integration
5. FDI-driven job creation

This transforms diagnostics from a cost line item into:

• A public health accelerator
• A manufacturing opportunity
• A workforce development engine
• A preparedness backbone

In other words: diagnostics as economic infrastructure.

Why This Matters Now

Three forces are converging:

1. Rising disease burden across cancer, diabetes, and infectious diseases
2. Post-pandemic urgency around surveillance and preparedness
3. Growing demand for local manufacturing and health sovereignty

Africa does not need more disconnected innovation.

It needs execution at scale.

A Question for Foundations and Development Partners

What if early disease detection became as fundamental as roads or electricity?

What if the billions already spent on diagnostics were recycled into local economies, creating jobs while saving lives?

What if diagnostics were designed not just to detect disease — but to strengthen systems?

This is not a theoretical exercise.

It is a solvable problem, at continental scale, with today’s technology.

The question is no longer if this can be done.

It is who will help make it real.

Call to Action: Build Africa’s Diagnostic Backbone — Together

Africa does not need another pilot.
It needs partners willing to build systems that last.

If you are a diagnostics company, life sciences innovator, manufacturer, or strategic investor looking to expand impact while unlocking long-term growth, this is an invitation to collaborate.

We are assembling a coalition to:

• Localize diagnostic manufacturing in Africa
• Scale saliva-based and non-invasive testing across priority diseases
• Integrate diagnostics with telehealth and care pathways
• Build national and regional platforms that governments can sustain
• Create skilled jobs, resilient supply chains, and long-term market access

Global leaders such as Thermo Fisher, Quest Diagnostics, Pfizer, and Moderna have already validated the scientific and commercial foundations of this approach. The next step is execution — on African soil, with African partners, at continental scale.

This is a classic FDI-driven platform play:

• Early movers shape standards
• Manufacturing anchors demand
• Ecosystem partners scale faster together than alone

If you believe diagnostics should prevent disease, not just confirm it, and if you see Africa as a strategic growth market rather than a short-term aid destination, let’s talk.

📩 Partner with us:
Reach out via 360Disruption to explore collaboration, co-investment, or deployment partnerships.

Africa’s diagnostic future will be built — the only question is who builds it.